We are international
• about imf TEXT SIZE   
imf funded research    back

Development of the antihelmintic flubendazole as a novel therapeutic agent for the treatment of multiple myeloma
Aaron Schimmer, MD, PhD, FRCPC
Princess Margaret Hospital
Ontario Cancer Institute
Toronto, ON, Canada
This project takes the unique approach of studying drugs approved by the FDA for other diseases to assess if they have unrecognized anti-myeloma activity. Any such drug can have an accelerated approval for myeloma use if significant anti-myeloma activity is demonstrated. Dr. Schimmer and colleagues have already identified that flubendazole, a drug used for intestinal worms, has anti-myeloma activity. The research team aims to advance the clinical development of flubendazole for myeloma by identifying biomarkers for use during a clinical trial and develop a Phase I clinical trial for this compound in patients with relapsed and refractory myeloma.
 related articles
Bone marrow microenvironment and multiple myeloma chemotherapy optimization
Characterization and preclinical evaluation of NKT cells in multiple myeloma
Mesenchymal cell cytotherapy for multiple myeloma
MMSET and epigenetic control in t(4;14) myelomas
Novel anti-myeloma therapy by targeting molecular signaling regulated by galectin family proteins
Reolysin: a novel reovirus-based therapy for multiple myeloma